The continuation of the Cancer Biology Training Program is proposed at the University of Michigan. The central goal of this program is to train exceptional junior investigators to address fundamental biological problems related to human cancer. The Cancer Biology Training Program is both multidisciplinary and interdepartmental, drawing its strength from the interdisciplinary cooperation of 41 faculty members from 15 basic science and clinical departments within The University of Michigan Medical School: Biological Chemistry, Molecular, Cellular and Developmental Biology, Dermatology, Human Genetics, Internal Medicine, Medicinal Chemistry, Microbiology &Immunology, Neurology, Otolaryngology, Pathology, Pediatrics, Pharmacology, Physiology, Radiation Oncology and Urology. The Program draws further strength from its association with The University of Michigan Comprehensive Cancer Center. The Program trains both predoctoral and postdoctoral scholars with research opportunities focusing on five specific areas of research: Cancer Genetics, Cancer Cell Biology, Molecular Therapeutics, Radiation Sciences and Molecular Imaging. Postdoctoral fellows will have completed a Ph.D. degree in one of the physical or biological sciences, or have completed an M.D. degree. Predoctoral students will comprise a subset of students already accepted into established graduate programs in Biological Chemistry, Cell and Developmental Biology, Cellular and Molecular Biology, Human Genetics, Microbiology and Immunology, Neurosciences, Pathology, Pharmacology, or Physiology. All trainees must have significant interest in pursing a career in some aspect of cancer-related research. This interdepartmental training program is dove-tailed into existing departmental programs while providing a cohesive, high quality training experience in cancer biology. Predoctoral trainees will be expected to graduate to outstanding postdoctoral positions, while postdoctoral trainees should assume leading academic and research positions.
| Haase, Santiago; Garcia-Fabiani, María Belén; Carney, Stephen et al. (2018) Mutant ATRX: uncovering a new therapeutic target for glioma. Expert Opin Ther Targets 22:599-613 |
| Morgan, Meredith A; Canman, Christine E (2018) Replication Stress: An Achilles' Heel of Glioma Cancer Stem-like Cells. Cancer Res 78:6713-6716 |
| Thomas, Tina T; Chukkapalli, Sahiti; Van Noord, Raelene A et al. (2018) Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts. J Vis Exp : |
| Rosselli-Murai, Luciana K; Yates, Joel A; Yoshida, Sei et al. (2018) Loss of PTEN promotes formation of signaling-capable clathrin-coated pits. J Cell Sci 131: |
| Pinatti, L M; Walline, H M; Carey, T E (2018) Human Papillomavirus Genome Integration and Head and Neck Cancer. J Dent Res 97:691-700 |
| Halbrook, Christopher J; Pasca di Magliano, Marina; Lyssiotis, Costas A (2018) Tumor cross-talk networks promote growth and support immune evasion in pancreatic cancer. Am J Physiol Gastrointest Liver Physiol 315:G27-G35 |
| Schofield, Heather K; Zeller, Jörg; Espinoza, Carlos et al. (2018) Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma. JCI Insight 3: |
| Wang, Qing; Yan, Ran; Pinnell, Nancy et al. (2018) Stage-specific roles for Zmiz1 in Notch-dependent steps of early T-cell development. Blood 132:1279-1292 |
| McDermott, Sarah C; Rodriguez-Ramirez, Christie; McDermott, Sean P et al. (2018) FGFR signaling regulates resistance of head and neck cancer stem cells to cisplatin. Oncotarget 9:25148-25165 |
| Hartlerode, Andrea J; Regal, Joshua A; Ferguson, David O (2018) Reversible mislocalization of a disease-associated MRE11 splice variant product. Sci Rep 8:10121 |
Showing the most recent 10 out of 185 publications
